BridgeBio Pharma (BBIO) Stock

PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a biopharmaceutical company that focuses on genetic diseases. Today, they announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for marketing authorization in the European Union (EU) for acoramidis, a treatment for wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM). In the Phase 3 study ATTRibute-CM, acoramidis demonstrated significant improvements in cardiovascular outcomes.

SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company working on oral macrocyclic peptides for hard-to-target diseases, has announced that BridgeBio Pharma, Inc. (Nasdaq: BBIO) has chosen to license some of the macrocyclic peptide candidates found through UNP's advanced AI-driven chemistry platform.

BridgeBio has received FDA approval for Attruby (acoramidis) to treat patients with ATTR-CM. The approval comes with a clear label that contains all important clinical information. Additionally, this approval activates a $500 million milestone payment to BridgeBio from a royalty-backed agreement made earlier this year, alleviating some regulatory and funding concerns for the company.

On Friday, BridgeBio announced that the U.S. Food and Drug Administration has approved its medication for a rare and serious heart condition. This makes it the first new treatment available in a market largely controlled by Pfizer's popular drug, Vyndaqel.

Attruby is the first and only approved treatment that clearly states it can nearly fully stabilize TTR. It has been proven to maintain the natural role of TTR in transporting thyroxine and vitamin A, and it also shows positive effects on heart health.

In Cohort 5 of PROPEL 2, taking infigratinib daily at a dose of 0.25mg/kg led to significant and lasting improvements in annualized height velocity (AHV). At Month 18, the average increase from the starting point was +2.50cm per year, with a p-value of 0.001.

A case study was written by both senior management at BridgeBio and Andrew W. Lo, Ph.D., who is a co-founder of BridgeBio and a professor at MIT.

Future decisions from the Food and Drug Administration could significantly increase the value of these stocks.

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company that focuses on genetic diseases, announced that it will present data from its ongoing long-term study of acoramidis in ATTR-CM at the American Heart Association (AHA) Scientific Sessions in Chicago from November 16 to 18, 2024. This presentation will include outcomes data collected over 42 months from the Phase 3 ATTRibute-CM study. Additionally, BridgeBio will showcase three posters during moderated sessions on ATTR-CM.